Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
Post navigation
Previous Post
Ag Genomics Begins to Bear Fruit